These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 1882349)

  • 1. Lack of teratogenicity of trans-2-ene-valproic acid compared to valproic acid in rats.
    Vorhees CV; Acuff-Smith KD; Weisenburger WP; Minck DR; Berry JS; Setchell KD; Nau H
    Teratology; 1991 Jun; 43(6):583-90. PubMed ID: 1882349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trans-2-ene-valproic acid is less behaviorally teratogenic than an equivalent dose of valproic acid in rats.
    Fisher JE; Acuff-Smith KD; Schilling MA; Nau H; Vorhees CV
    Teratology; 1994 Jun; 49(6):479-86. PubMed ID: 7747269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teratogenicity and developmental toxicity of valproic acid in rats.
    Vorhees CV
    Teratology; 1987 Apr; 35(2):195-202. PubMed ID: 3110992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teratogenicity of carbamazepine in rats.
    Vorhees CV; Acuff KD; Weisenburger WP; Minck DR
    Teratology; 1990 Mar; 41(3):311-7. PubMed ID: 2326755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teratogenic effects of sodium valproate in mice and rats at midgestation and at term.
    Menegola E; Broccia ML; Nau H; Prati M; Ricolfi R; Giavini E
    Teratog Carcinog Mutagen; 1996; 16(2):97-108. PubMed ID: 8875740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition of valproic acid in maternal, fetal, and newborn sheep. II: metabolism and renal elimination.
    Kumar S; Wong H; Yeung SA; Riggs KW; Abbott FS; Rurak DW
    Drug Metab Dispos; 2000 Jul; 28(7):857-64. PubMed ID: 10859160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproic acid-induced placental and teratogenic effects in rats.
    Khera KS
    Teratology; 1992 Jun; 45(6):603-10. PubMed ID: 1345037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valproic acid in pregnancy: how much are we endangering the embryo and fetus?
    Ornoy A
    Reprod Toxicol; 2009 Jul; 28(1):1-10. PubMed ID: 19490988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myo-inositol enhances teratogenicity of valproic acid in the mouse.
    Massa V; Wlodarczyk B; Giavini E; Finnell RH
    Birth Defects Res A Clin Mol Teratol; 2006 Mar; 76(3):200-4. PubMed ID: 16511884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teratogenic effects of valproic acid and diphenylhydantoin on mouse embryos in culture.
    Bruckner A; Lee YJ; O'Shea KS; Henneberry RC
    Teratology; 1983 Feb; 27(1):29-42. PubMed ID: 6405496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxamic acid and fluorinated derivatives of valproic acid: anticonvulsant activity, neurotoxicity and teratogenicity.
    Gravemann U; Volland J; Nau H
    Neurotoxicol Teratol; 2008; 30(5):390-4. PubMed ID: 18455366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereoselective dysmorphogenicity of the enantiomers of the valproic acid analogue 2-N-propyl-4-pentynoic acid (4-yn-VPA): cross-species evaluation in whole embryo culture.
    Andrews JE; Ebron-McCoy MT; Bojic U; Nau H; Kavlock RJ
    Teratology; 1997 May; 55(5):314-8. PubMed ID: 9261925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transfer of valproic acid and its main active unsaturated metabolite to the gestational tissue: correlation with neural tube defect formation in the mouse.
    Nau H
    Teratology; 1986 Feb; 33(1):21-7. PubMed ID: 3090732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics of valproic acid in pregnant sheep after maternal and fetal intravenous bolus administration.
    Gordon JD; Riggs KW; Rurak DW; Kwan E; Hall C; Abbott FS
    Drug Metab Dispos; 1995 Dec; 23(12):1383-9. PubMed ID: 8689948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spina bifida aperta induced by valproic acid and by all-trans-retinoic acid in the mouse: distinct differences in morphology and periods of sensitivity.
    Ehlers K; Stürje H; Merker HJ; Nau H
    Teratology; 1992 Aug; 46(2):117-30. PubMed ID: 1440416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valproic acid in amygdala-kindled rats: alterations in anticonvulsant efficacy, adverse effects and drug and metabolite levels in various brain regions during chronic treatment.
    Löscher W; Fisher JE; Nau H; Hönack D
    J Pharmacol Exp Ther; 1989 Sep; 250(3):1067-78. PubMed ID: 2506334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of attenuation of valproic acid-induced effects by folinic acid in rat embryos in vitro.
    Hansen DK; Grafton TF
    Teratology; 1991 Jun; 43(6):575-82. PubMed ID: 1882348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status.
    Tang W; Borel AG; Fujimiya T; Abbott FS
    Chem Res Toxicol; 1995; 8(5):671-82. PubMed ID: 7548749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans.
    Kassahun K; Farrell K; Abbott F
    Drug Metab Dispos; 1991; 19(2):525-35. PubMed ID: 1676665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of supplemental folic acid on valproic acid-induced embryotoxicity and tissue zinc levels in vivo.
    Hansen DK; Grafton TF; Dial SL; Gehring TA; Siitonen PH
    Teratology; 1995 Nov; 52(5):277-85. PubMed ID: 8838251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.